Galera Therapeutics, Inc. has announced the scheduling of its Combined 2025 and 2026 Annual Meeting of Stockholders for May 8, 2026. This meeting is significant as it comes more than 60 days after the anniversary of the previous Annual Meeting held on February 24, 2025. The company is providing a new deadline for stockholders to submit any qualified proposals or nominations. Stockholders wishing to bring a director nomination or proposal must comply with the requirements set forth in the company's Amended and Restated Bylaws. The notice must be delivered to the secretary of the company, Joel Sussman, at the principal executive office by April 13, 2026. Additionally, stockholders intending to solicit proxies in support of director nominees other than the company's nominees must provide notice to the company by the same date. Proposals for inclusion in the company's proxy materials must also be received by April 13, 2026. The principal executive office is located at 101 Lindenwood Drive, Suite 225, Malvern, Pennsylvania 19355.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.